Amplification of c-erbB-2, int-2 and c-myc Genes in Node-Negative Breast Carcinomas: Relationship to Prognosis

References

• Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• Paterson M C, Dietrich K D, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node negative breast cancer. Cancer Res 1991; 51: 556–67
   PubMed Web of Science ®Google Scholar
• Coussens L, Yang-Feng T L, Liao Y C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with new oncogene. Science 1985; 230: 1132–9
   PubMed Web of Science ®Google Scholar
• Bargmann C I, Weinberg R A. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988; 7: 2043–52
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230–4
   PubMed Web of Science ®Google Scholar
• Lupu R, Colomer R, Zugmaier G, et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 1990; 249: 1552–5
   PubMed Web of Science ®Google Scholar
• Yarden Y, Weinberg R A. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc Natl Acad Sci USA 1989; 86: 3179–83
   PubMed Web of Science ®Google Scholar
• Huang S S, Koh H A, Konish Y, Bullock L D, Huang S J. Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart. J Biol Chem 1990; 265: 3340–6
   PubMed Web of Science ®Google Scholar
• Dobashi K, Davis J G, Mikami Y, Freeman J K, Hamuro J, Greene M I. Characterization of a neu/c-erbB-2 protein-specific activating factor. Proc Natl Acad Sci USA 1991; 88: 8582–6
   PubMed Web of Science ®Google Scholar
• Tarakhovsky A, Zaichuk T, Prassolov V, Butenko Z A. A 25 kDa polypeptide is the ligand for p185 neu and is secreted by activated macrophages. Oncogene 1991; 6: 2187–96
   PubMed Web of Science ®Google Scholar
• Paik S, Hazan R, Fisher E R, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of c-erbB-2 protein overexpression in primary breast cancer. J. Clin Oncol 1990; 8: 103–12
   Web of Science ®Google Scholar
• Lovekin C, Ellis I O, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439–43
   PubMed Web of Science ®Google Scholar
• Gullick W J, Love S B, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434–8
   PubMed Web of Science ®Google Scholar
• Winstanley J, Cooke T, Murray G D, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447–50
   PubMed Web of Science ®Google Scholar
• Ali I U, Campell G, Lidereau R, Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res 1988; 3: 1–8
   Google Scholar
• Zhou D-J, Ahuja H, Cline M J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 4: 105–8
   PubMed Web of Science ®Google Scholar
• van der Vijver M J, Peterse J L, Mooi W J, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239–45
   Google Scholar
• Thor A D, Schwartz L H, Koerner F C, et al. Analysis of c-erbB-2 expression in bredst carcinomas with clinical follow-up. Cancer Res 1989; 49: 7147–52
   PubMed Web of Science ®Google Scholar
• Clark G M, McGuire W L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944–8
   PubMed Web of Science ®Google Scholar
• Borg Å, Tandon A K, Sigurdsson H, et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332–7
   PubMed Web of Science ®Google Scholar
• Nusse R. The int genes in mammary tumorigenesis and in normal development. Trends Genet 1988; 4: 291–5
   PubMed Web of Science ®Google Scholar
• Lidereau R, Callahan R, Dickson C, Peters G, Escot C, Ali I U. Amplification of the int-2 gene in primary human breast tumours. Oncogene Res 1988; 2: 285–91
   PubMedGoogle Scholar
• Tsuda H, Hirahashi S, Shimosato Y. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplifications units: HST-l/int-2 and c-erbB-2/ear-l. Cancer Res 1989; 49: 3104–8
   PubMed Web of Science ®Google Scholar
• Machotka S V, Garrett C T, Schwartz A M, Callahan R. Amplification of the proto-oncogene int-2, c-erbB-2 and c-myc in human breast cancer. Clin Chimica Acta 1989; 184: 207–18
   PubMed Web of Science ®Google Scholar
• Borg Å, Sigurdsson H, Clark G M, et al. Association of int-2/hst1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 1991; 63: 136–42
   PubMed Web of Science ®Google Scholar
• Escot C, Theillet C, Lidereau R, et al. Genetic alteration of the c-myc protooncogene in primary human breast carcinoma. Proc Natl Acad Sci USA 1986; 83: 4834–8
   PubMed Web of Science ®Google Scholar
• Seshadri R, Matthews C, Dobrovic A, Horsfall D J. The significance of oncogene amplification in primary breast cancer. Int J Cancer 1989; 43: 270–2
   PubMed Web of Science ®Google Scholar
• Varley J M, Swallow J E, Brammar W J, Whittaker J L, Walker R A. Alterations to either c-erbB-2 (neu) or c-myc proto-onco-genes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987; 1: 423–30
   PubMed Web of Science ®Google Scholar
• Meyers S L, O'Brien M T, Smith T, Dudley J P. Analysis of the int-I, int-2, c-myc and neu oncogenes in human breast carcinomas. Cancer Res 1990; 50: 5911–82
   Google Scholar
• Bonilla M, Ramirez M, Lopez-Cueto J, Garigilo P. In vivo amplification and rearrangements of c-rnyc oncogene in human breast tumours. J Natl Cancer lnst 1988; 80: 665–71
   PubMedGoogle Scholar
• Tavassoli M, Quirke P, Farzaneh F, Lock N J, Mayne L V, Kirkham N. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinomas. Br J Cancer 1989; 60: 505–10
   Google Scholar
• Bsrresen A-L, Ottestad L, Gaustad A, et al. Amplification and protein overexpression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990; 62: 585–90
   Google Scholar
• Casey G, Smith R, McGillirray P, Peters G, Dickson C. Characterization and chromosome assignment of the human homolog of int-2, a potential protooncogene. Mol Cell Biol 1986; 6: 502–10
   PubMed Web of Science ®Google Scholar
• Favera R D, Gelmann E P, Martinotti S, et al. Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc Natl Acad Sci USA 1982; 79: 6497–501
   PubMed Web of Science ®Google Scholar
• Feinberg A P, Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6–13
   PubMed Web of Science ®Google Scholar
• Myers J, Dickson L C, Dewet W J, et al. Analysis of the 3′ end of the human proα2(I) collagen gene. J Biol Chem 1983; 258: 10128–35
   PubMedGoogle Scholar
• Tandon A K, Clark G M, Chamness G C, Ullrich A, McGuire W L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120–8
   PubMed Web of Science ®Google Scholar
• Barnes D M, Lammie G A, Willis R R, Gullick W J, Allen D S, Altman D G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 1988; 58: 448–52
   PubMed Web of Science ®Google Scholar
• Gusterson B A, Machin L G, Gullick W J, et al. C-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1988; 58: 453–7
   PubMed Web of Science ®Google Scholar
• Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087–90
   PubMed Web of Science ®Google Scholar
• Perren T J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 1991; 63: 328–32
   PubMed Web of Science ®Google Scholar
• The Ludwig Breast Cancer Study: combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 677–83
   Google Scholar